Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1480345
This article is part of the Research Topic Mechanisms of Traumatic Brain Injury and its Pharmacotherapy View all articles

Fisetin exerts neuroprotective effects in vivo and in vitro by inhibiting ferroptosis and oxidative stress after traumatic brain injury

Provisionally accepted
Haiyi Yang Haiyi Yang 1Ye Hong Ye Hong 2*Mingjie Gong Mingjie Gong 1*Shihong Cai Shihong Cai 1*Zhongwen Yuan Zhongwen Yuan 1*SENLING FENG SENLING FENG 1Qibo Chen Qibo Chen 3*Liu Xixia Liu Xixia 3*Zhengrong Mei Zhengrong Mei 1*
  • 1 Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • 2 Guangzhou Eighth People's Hospital, Guangzhou, Guangdong Province, China
  • 3 People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Region, China

The final, formatted version of the article will be published soon.

    Traumatic brain injury (TBI) is an important cause of disability and mortality, and identifying effective neuroprotective drugs and targets after TBI is an urgent public concern. Ferroptosis, an iron dependent, novel form of cell death associated with lipid peroxidation, has recently been shown to participate in secondary injury processes after TBI. Fisetin is a natural and relatively safe at general dosages flavonoid compound with neuroprotective properties. This study aimed to investigate the molecular mechanism of ferroptosis in TBI and the role of fisetin in neuroprotection by regulating ferroptosis and oxidative stress following TBI. Through in vivo experiments, a mouse model of repetitive mild closed head injury was established to determine that fisetin could reduce post-TBI injury and exert neuroprotective effects as determined by the Neurobehavioral Severity Scale score, brain water content, Nissl staining, hematoxylin-eosin staining, TUNEL staining and water maze experiment results. Fisetin was proven to be capable of inhibiting the changes in post-TBI ferroptosis proteins, activating the PI3K/AKT/NRF2 signaling pathway, and reducing oxidative stress, as confirmed by Western blotting. Via in vivo experiments, cell death models of ferroptosis were established with glutamate and erastin. As determined by MTT assay, fisetin improved the survival of cells with induced ferroptosis. The morphological alterations of ferroptotic cells were ascertained with a microscope. Fisetin similarly inhibited the changes in multiple ferroptosis-associated proteins induced by glutamate and erastin, reduced ROS and peroxidation products, and increased the level of antioxidants. In conclusion, fisetin exerts neuroprotective effects in TBI through multiple pathways, thereby alleviating tissue damage and cognitive dysfunction.

    Keywords: Fisetin, ferroptosis, Traumatic Brain Injury, Oxidative Stress, PI3K/AKt/Nrf2

    Received: 13 Aug 2024; Accepted: 07 Nov 2024.

    Copyright: © 2024 Yang, Hong, Gong, Cai, Yuan, FENG, Chen, Xixia and Mei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Ye Hong, Guangzhou Eighth People's Hospital, Guangzhou, 510000, Guangdong Province, China
    Mingjie Gong, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Shihong Cai, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Zhongwen Yuan, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
    Qibo Chen, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Region, China
    Liu Xixia, People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Region, China
    Zhengrong Mei, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.